A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

Alessandra Tedeschi; Richard Greil; Fatih Demirkan; Tadeusz Robak; Carol Moreno; Paul M. Barr; Bertrand Anz; David Simpson; Gianluca Gaidano; Osnat Bairey; Don Stevens; Devinder Gill; Ian W. Flinn; Thomas J. Kipps; Jan A. Burger; Jennifer Lin; Thomas Webb; Viktor Fedorov; Lori Styles; John G. Gribben

doi:10.3324/haematol.2019.223743

A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

Alessandra Tedeschi
, Richard Greil
, Fatih Demirkan
, Tadeusz Robak
, Carol Moreno
, Paul M. Barr
, Bertrand Anz
, David Simpson
, Gianluca Gaidano
, Osnat Bairey
, Don Stevens
, Devinder Gill
, Ian W. Flinn
, Thomas J. Kipps
, Jan A. Burger
, Jennifer Lin
, Thomas Webb
, Viktor Fedorov
, Lori Styles
, John G. Gribben

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Lettera › peer review

Lingua originale	Inglese
pagine (da-a)	E164-E168
Rivista	Haematologica
Volume	105
Numero di pubblicazione	4
DOI	https://doi.org/10.3324/haematol.2019.223743
Stato di pubblicazione	Pubblicato - 2020

Accesso al documento

10.3324/haematol.2019.223743

Altri file e collegamenti

Link to publication in Scopus

Cita questo

Tedeschi, A., Greil, R., Demirkan, F., Robak, T., Moreno, C., Barr, P. M., Anz, B., Simpson, D., Gaidano, G., Bairey, O., Stevens, D., Gill, D., Flinn, I. W., Kipps, T. J., Burger, J. A., Lin, J., Webb, T., Fedorov, V., Styles, L., & Gribben, J. G. (2020). A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Haematologica, 105(4), E164-E168. https://doi.org/10.3324/haematol.2019.223743

@article{7a849aa468bf4e93b3089ea2c9acb6cc,

title = "A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma",

author = "Alessandra Tedeschi and Richard Greil and Fatih Demirkan and Tadeusz Robak and Carol Moreno and Barr, \{Paul M.\} and Bertrand Anz and David Simpson and Gianluca Gaidano and Osnat Bairey and Don Stevens and Devinder Gill and Flinn, \{Ian W.\} and Kipps, \{Thomas J.\} and Burger, \{Jan A.\} and Jennifer Lin and Thomas Webb and Viktor Fedorov and Lori Styles and Gribben, \{John G.\}",

note = "Funding Information: Funding: this study was sponsored by Pharmacyclics LLC, an AbbVie Company. Editorial support was provided by Emily Chastain, PhD, an employee of Pharmacyclics LLC, an AbbVie Company. Correspondence: ALESSANDRA TEDESCHI. [email protected] doi:10.3324/haematol.2019.223743 Information on authorship, contributions, and financial \& other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.",

year = "2020",

doi = "10.3324/haematol.2019.223743",

language = "English",

volume = "105",

pages = "E164--E168",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "4",

}

Tedeschi, A, Greil, R, Demirkan, F, Robak, T, Moreno, C, Barr, PM, Anz, B, Simpson, D, Gaidano, G, Bairey, O, Stevens, D, Gill, D, Flinn, IW, Kipps, TJ, Burger, JA, Lin, J, Webb, T, Fedorov, V, Styles, L & Gribben, JG 2020, 'A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma', Haematologica, vol. 105, n. 4, pagg. E164-E168. https://doi.org/10.3324/haematol.2019.223743

A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. / Tedeschi, Alessandra; Greil, Richard; Demirkan, Fatih et al.
In: Haematologica, Vol. 105, N. 4, 2020, pag. E164-E168.

Risultato della ricerca: Contributo su rivista › Lettera › peer review

TY - JOUR

T1 - A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

AU - Tedeschi, Alessandra

AU - Greil, Richard

AU - Demirkan, Fatih

AU - Robak, Tadeusz

AU - Moreno, Carol

AU - Barr, Paul M.

AU - Anz, Bertrand

AU - Simpson, David

AU - Gaidano, Gianluca

AU - Bairey, Osnat

AU - Stevens, Don

AU - Gill, Devinder

AU - Flinn, Ian W.

AU - Kipps, Thomas J.

AU - Burger, Jan A.

AU - Lin, Jennifer

AU - Webb, Thomas

AU - Fedorov, Viktor

AU - Styles, Lori

AU - Gribben, John G.

N1 - Funding Information: Funding: this study was sponsored by Pharmacyclics LLC, an AbbVie Company. Editorial support was provided by Emily Chastain, PhD, an employee of Pharmacyclics LLC, an AbbVie Company. Correspondence: ALESSANDRA TEDESCHI. [email protected] doi:10.3324/haematol.2019.223743 Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.

PY - 2020

Y1 - 2020

UR - https://www.scopus.com/pages/publications/85083270668

U2 - 10.3324/haematol.2019.223743

DO - 10.3324/haematol.2019.223743

M3 - Letter

SN - 0390-6078

VL - 105

SP - E164-E168

JO - Haematologica

JF - Haematologica

IS - 4

ER -